Skip to main content
Publications
Pascal R, Crovetto F, Casas I, Youssef L, Trilla C, Larroya M, Cahuana A, Boada D, Foraster M , Llurba E, Sunyer J, Crispi F, Gratacos E, Gomez-Roig MD. Impact of the COVID-19 pandemic on maternal well-being during pregnancy . J Clin Med. 2022 Apr 15;11(8):2212. doi: 10.3390/jcm11082212
Richardson D , Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M , Odom D , Hollis K , Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application . Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7
Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L , Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer . Breast Cancer Res Treat. 2021 Apr;186(3):839-50. doi: 10.1007/s10549-020-06038-x
Vilanova MB, Franch-Nadal J, Falguera M, Marsal JR , Canivell S, Rubinat E, Miro N, Mollo A, Mata-Cases M, Gratacos M, Castelblanco E, Mauricio D. Prediabetes is independently associated with subclinical carotid atherosclerosis: an observational study in a non-urban Mediterranean population . J Clin Med. 2020 Jul 7;9(7):2139. doi: 10.3390/jcm9072139
Koziel M, Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ , Brandes A, Paquette M, Zint K, Franca LR, Lu S, Bartels DB, Huisman MV, Lip GYH. Persistence with anticoagulation for atrial fibrillation: report from the GLORIA-AF Phase III 1-year follow-up . J Clin Med. 2020 Jun 23;9(6):1969. doi: 10.3390/jcm9061969
Liede A, Mansfield CA , Metcalfe KA, Price MA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment . Breast Cancer Res Treat. 2017 Sep;165(2):433-44. doi: 10.1007/s10549-017-4332-3.
Dine JL , O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl . Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.